BioNxt Gets Positive Report from European Patent Office for Sublingual Anticancer Drug Delivery Patent

BioNxt Solutions Inc., headquartered in Vancouver, recently received a favorable international examination report from the European Patent Office regarding their patent application for sublingual delivery of anticancer drugs aimed at treating autoimmune neurodegenerative diseases. The company anticipates the EU patent will be granted within eight weeks and plans to quickly enter the national phase of the Patent Cooperation Treaty process, with applications prepared for the US, Canada, China, Japan, Australia, and other regions.

BioNxt is focused on advancing its portfolio of patents concerning orally dispersible films (ODFs) that contain potent anticancer compounds for the treatment of neurodegenerative diseases. The company intends to file related provisional patent applications in the EU, expecting to secure three to four patents across major international jurisdictions by late 2025 to early 2026. These patents could offer protection until 2045.

The company's leading initiative involves developing a proprietary ODF form of Cladribine, targeting the multiple sclerosis (MS) market. Cladribine tablets, already approved in over 75 countries including by the FDA and the European Medicines Agency, achieved sales exceeding one billion USD in 2023, as reported by Merck KGaA. These tablets are prescribed for highly active forms of relapsing-remitting MS, a condition affecting approximately 2.3 million people globally, with the highest rates in North America and Europe. The global market for MS drugs is projected to exceed 41 billion USD by 2033, according to Market.us.

In addition to its MS-focused efforts, BioNxt is introducing a new clinical application using anticancer compounds in an ODF delivery system for Myasthenia Gravis (MG). MG is an autoimmune and neuromuscular disorder marked by muscle weakness and fatigue. Like MS patients, those with MG often experience dysphagia, making ODF drug products particularly advantageous over traditional tablets. The global market for MG is forecasted to reach 6.7 billion USD by 2032.

Overall, the increasing prevalence of Central Nervous System (CNS) diseases is expected to drive further investment in new drugs and delivery systems. The market for drugs treating CNS diseases is anticipated to grow significantly, potentially reaching 238.8 billion USD by 2032, as per GMI Market Insights.

BioNxt Solutions Inc. operates as a bioscience accelerator, concentrating on next-generation drug formulations and delivery systems, diagnostic screening tests, and the development of new active pharmaceutical ingredients. Their expertise includes precision transdermal and oral dissolvable drug formulations, rapid infectious disease and oral health screening tests, and the clinical evaluation of new pharmaceutical ingredients for neurological applications. The company has research and development facilities in North America and Europe, with a particular operational focus in Germany, and is currently working towards regulatory approval and commercialization of medical products for the European markets.